{
    "clinical_study": {
        "@rank": "72128", 
        "arm_group": {
            "arm_group_label": "AutoloGel", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will be treated with AutoloGel on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All patients will receive Autologel treatment"
        }, 
        "brief_summary": {
            "textblock": "The aim of this trial is to demonstrate the effectiveness of complete wound healing in a\n      prospective, open-label, case-matched cohort-controlled trial in which pressure ulcers will\n      be treated using AutoloGel and standard care and case-matched against a concurrent cohort of\n      patients receiving undefined Usual and Customary Care."
        }, 
        "brief_title": "AutoloGel Therapy to Usual and Customary Care in Pressure Ulcers", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Pressure Ulcer", 
        "condition_browse": {
            "mesh_term": [
                "Pressure Ulcer", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "Pressure ulcers (PUs) are a common problem in all patient care settings, especially\n      long-term acute care facilities and nursing homes. AutoloGel is a platelet-rich plasma gel\n      used in the treatment of non-healing chronic wounds. The results of AutoloGel to date when\n      used to treat PUs have been promising. The aim of this trial is to demonstrate the\n      effectiveness of complete wound healing in a prospective, open-label, case-matched cohort\n      trial in which pressure ulcers will be treated using AutoloGel and standard of care to\n      determine time to heal at 16 weeks. Comparison will be made with a case matched concurrent\n      cohort of patients receiving undefined Usual and Customary Care."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Medicare/Medicaid eligible\n\n          2. \u226518 years of age\n\n          3. Ulcer of pressure/shear etiology (Stage II, III, and IV, see Appendix 9 for stage\n             definitions)\n\n          4. The largest non-healing wound, if multiple wounds are present, or the single wound to\n             be treated (Index Ulcer) that is located on the heel, ischium, sacrum, and trochanter\n\n          5. For subjects with potentially multiple eligible PUs, the largest ulcer will be\n             selected.\n\n             There must be at least 4 cm between the Index Ulcer and other ulcers; if all ulcers\n             are closer than 4 cm, the subject should not be enrolled (screen failure)\n\n          6. Debrided ulcer size between 3 cm2 and 200 cm2\n\n          7. Demonstrated adequate offloading regimen\n\n          8. Duration \u2265 1 month at first visit\n\n          9. Subject must be willing to comply with the Protocol, which will be assessed by\n             enrolling clinician.\n\n        Exclusion Criteria:\n\n          1. Subjects known to be sensitive to AutoloGel components (calcium chloride, thrombin,\n             ascorbic acid) and/or materials of bovine origin\n\n          2. Stage I pressure ulcers\n\n          3. Ulcers that are unstageable or of deep tissue morphology that have yet to become an\n             open wound\n\n          4. Presence of another wound that is concurrently treated and might interfere with\n             treatment of index wound by AutoloGel\n\n          5. Ulcer not of PU pathophysiology (e.g., pure diabetic, vasculitic, radiation,\n             rheumatoid, collagen vascular disease, venous, or arterial etiology)\n\n          6. Any malignancy other than non-melanoma skin cancer\n\n          7. Subjects who are cognitively impaired and do not have a healthcare proxy\n\n          8. Serum albumin of less than 2.5 g/dL\n\n          9. Plasma Platelet count of less than 100 x 109/L\n\n         10. Hemoglobin of less than 10.5 g/dL\n\n         11. Subject has inadequate venous access for repeated blood draw required for AutoloGel\n             Administration.\n\n        10. Life expectancy of < 6 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01819142", 
            "org_study_id": "CM004"
        }, 
        "intervention": {
            "arm_group_label": "AutoloGel", 
            "description": "AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.", 
            "intervention_name": "AutoloGel", 
            "intervention_type": "Device", 
            "other_name": "Autologel System"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "non healing wound", 
            "pressure ulcer"
        ], 
        "lastchanged_date": "March 27, 2013", 
        "number_of_arms": "1", 
        "official_title": "A Multi-Center, Prospective, Cohort Trial Comparing the Effectiveness of AutoloGel Therapy to Usual and Customary Care in Stage II-IV Pressure Ulcers", 
        "overall_contact": {
            "email": "jearabino@cytomedix.com", 
            "last_name": "Jackie Earabino, RNN"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Compare complete wound healing at 16 weeks for all pressure ulcers treated with AutoloGel plus standard of care with case-matched concurrent controls. Complete wound closure is defined as skin re-epithelialization without drainage or dressing requirements confirmed at two consecutive study visits 2 weeks apart (FDA Guidance for Industry Chronic Cutaneous Ulcer and Burn Wounds \u2500 Developing Products for Treatment, 2006).", 
            "measure": "Time to complete wound healing", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01819142"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Frequency of ulcer recurrence (recurrence defined as any new ulcer that has appeared since the Index Ulcer healed)", 
                "measure": "Ulcer recurrence", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Proportion of patients with completely healed pressure ulcers", 
                "measure": "Proportion of healed ulcers", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "description": "Change in mean W-QOL (Quality of Life with Chronic Wounds) score between baseline and 16 weeks", 
                "measure": "W-QOL (Quality of Life with Chronic Wounds) score", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "description": "Frequency and severity of adverse events during the study", 
                "measure": "Number of patients with adverse events as a measure of tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "16 weeks"
            }
        ], 
        "source": "Cytomedix", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cytomedix", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}